The clinical significance of PD-L1-positive (PD-L1+) CTCs in NSCLC is to date in its infancy as the first related study was published in 2016 by Schehr and colleagues [23], who initially focused on technical optimizations of PD-L1+ CTC enrichment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.